sarilumab low dose (200mg) - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.23 [0.49, 3.12]< 10%1 study (1/-)33.1 %NAnot evaluable crucial-
clinical improvement 1.03 [0.75, 1.41]> 10%1 study (1/-)57.4 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.03 [0.75, 1.41]> 10%1 study (1/-)57.4 %NAnot evaluable important-

safety endpoints 00

serious adverse events 1.15 [0.62, 2.12]< 10%1 study (1/-)32.9 %NAnot evaluable important-
adverse events 0.97 [0.56, 1.69]< 10%1 study (1/-)54.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.